Seattle Genetics, Mabtech cancer MAb deal

Mabtech (Nacka, Sweden) granted SGEN an exclusive license to certain monoclonal antibodies that target cell surface molecules on a variety of cancer cells. SGEN said it will evaluate the antibodies as...